New Stock News | The Prospectus for Tangji Medical's IPO on the Hong Kong Stock Exchange Has Lapsed

Hangzhou Tangji Medical Technology Co., Ltd. (referred to as: Tangji Medical) submitted its Hong Kong stock prospectus on February 9, 2026, which will expire six months later on August 9, 2026. China International Capital Corporation and Caitong International are its joint sponsors at the time of submission. The prospectus reveals that Tangji Medical is a medical device company based in China, focusing on providing innovative solutions for the treatment and full-cycle management of metabolic diseases. The company's strategy has established a product pipeline that includes medical devices and corresponding management products for treating obesity and metabolic diseases. All products are centered on the treatment and management of metabolic diseases, with indications including overweight, obesity, obesity-related MASH, and obesity-related type 2 diabetes.